title: [Primary gastrointestinal lymphomas: response to eradicative therapy and prognostic factors in 52 patients].
abstract: BACKGROUND
  To analyze the response to eradicative therapy and prognostic factors in 52 patients with primary gastrointestinal lymphoma (PGIL) diagnosed at a single institution in a 13 year period.
  
  
  METHODS
  The main clinical, biological and evolutive data were recorded. Pathologic diagnosis of PGIL was made according to the Working Formulation. Clinical stage was determined by the Ann Arbor system modified by Mushoff. The results of therapy as well as the influence of such characteristics on complete remission (CR), disease-free survival (DFS) and overall survival (OS) were studied.
  
  
  RESULTS
  Mean age of the series was 53 years (SD 15). Thirty patients were males. HIV infection preceded PGIL diagnosis in 10 cases. Seventeen had bad performance status (ECOG 2-4) and 30 B symptoms. The PGIL localization was gastric in 31 cases and 29 had a low grade malignant lymphoma. B phenotype was demonstrated in 98% and 22 patients presented advanced stages (IIE2-IV). Treatment was radical surgery followed by intensive chemotherapy in 32 cases, intensive chemotherapy alone in 17, and surgical resection in 3. CR was obtained in 34 patients and 6 of them relapsed. The projected DFS from CR at 9 years was 72% and OS was 26%. CR and survival were not influenced by PGIL localization and treatment type. The main unfavourable prognostic factors were advanced stage (CR and OS), B symptoms (DFS and OS) and advanced ECOG score (CR, DFS and OS). Previous HIV infection had an independent prognostic influence on both CR and OS.
  
  
  CONCLUSIONS
  In patients with PGIL, the achievement of CR, DFS and survival have been independent of the type of eradicative treatment used. Performance status, B symptoms and clinical stage have been the main prognostic factors. HIV infection carried an independent prognostic significance.
authors.affiliation: Servicio de Hematología-Hemoterapia, Hospital Universitari Germans Trias i Pujol, Badalona.
authors.forename: J A
authors.initials: JA
authors.lastname: Hernández
authors.forename: J M
authors.initials: JM
authors.lastname: Ribera
authors.forename: A
authors.initials: A
authors.lastname: Oriol
authors.forename: M
authors.initials: M
authors.lastname: Batlle
authors.forename: M
authors.initials: M
authors.lastname: Vaquero
authors.forename: A
authors.initials: A
authors.lastname: Flores
authors.forename: J
authors.initials: J
authors.lastname: Fernández-Llamazares
authors.forename: M
authors.initials: M
authors.lastname: Piñol
authors.forename: F
authors.initials: F
authors.lastname: Millá
authors.forename: E
authors.initials: E
authors.lastname: Feliu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents
vernacular_title: Linfomas gastrointestinales primarios: respuesta al tratamiento erradicativo y factores pronósticos en 52 pacientes.